Why Is Entrectinib (Rozlytrek) So Hard to Find? [Explained for 2026]

If you've been prescribed Entrectinib (brand name Rozlytrek) and gone to your local pharmacy only to be turned away, you're not alone. This targeted cancer therapy is one of the most prescribed tyrosine kinase inhibitors for ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors — but it's almost never available at your corner drugstore. Here's why, and what you can do about it in 2026.

What Is Entrectinib (Rozlytrek)?

Entrectinib is a multikinase inhibitor approved by the FDA in August 2019 and manufactured by Genentech (a member of the Roche Group). It's sold under the brand name Rozlytrek and is indicated for adults with ROS1-positive metastatic non-small cell lung cancer (NSCLC), as well as adults and children older than 1 month with solid tumors that have an NTRK gene fusion. There is currently no FDA-approved generic version of Rozlytrek.

Why Can't I Pick It Up at a Regular Pharmacy?

Entrectinib is classified as a specialty medication, which means it is only dispensed through designated specialty pharmacies. Genentech and most insurers require the drug to be obtained via specialty pharmacy channels for several reasons:

Prior authorization is almost always required. Insurers need to verify the biomarker result (ROS1 or NTRK gene fusion) before approving the prescription, a process that retail pharmacies aren't equipped to manage.

High cost requires financial coordination. At roughly $8,000 per 28-day supply, Rozlytrek requires copay assistance programs, benefits investigations, and insurance coordination that specialty pharmacies are trained to handle.

Ongoing clinical monitoring. Patients on entrectinib require regular lab monitoring for liver function, heart function (LVEF), uric acid levels, and other parameters that specialty pharmacists are trained to support.

Low prescription volume. ROS1 gene fusions occur in only 1–2% of NSCLC cases, and NTRK fusions are rare across all solid tumors. This low demand means retail pharmacies rarely stock it.

Is There an Entrectinib Shortage in 2026?

As of 2026, entrectinib is not listed on the FDA Drug Shortages Database. However, patients frequently report difficulty filling their prescription promptly because the specialty pharmacy network is limited and prior authorization delays can stretch the process out by days or even weeks. This is not the same as a formal drug shortage — but it can feel just as frustrating.

The most common access barriers patients encounter include:

Prior authorization denials or delays from their insurer

Specialty pharmacy not contracted with their insurance plan

Waiting for biomarker testing results before the prescription can be processed

Financial assistance paperwork taking time to process

Which Specialty Pharmacies Carry Entrectinib?

Rozlytrek is distributed through a network of specialty pharmacy partners. Your oncologist's office or Genentech Access Solutions (877-436-3683) can help identify which specialty pharmacy is in-network for your insurance plan. Common specialty pharmacy channels for Rozlytrek include Specialty Pharmacy networks affiliated with large health systems, CVS Specialty, Walgreens Specialty, and AllianceRx Walgreens Prime. Your insurer may have a preferred specialty pharmacy that affects your copay.

What Can You Do If You Can't Get Your Entrectinib Filled?

There are several steps you can take right now if your prescription is stuck:

Contact Genentech Access Solutions. Call 877-436-3683 Monday–Friday. They can perform a benefits investigation, identify the right specialty pharmacy, and help initiate prior authorization.

Ask your oncologist's office for help. Most oncology practices have dedicated pharmacy liaisons who manage specialty drug access for their patients daily.

Appeal a prior authorization denial. If your PA was denied, you have the right to appeal. Your oncologist can submit clinical documentation supporting your case. Genentech provides sample appeal letters.

Use medfinder to locate pharmacies. medfinder contacts pharmacies near you on your behalf to find out which ones can fill your prescription — saving you the time and frustration of calling around yourself.

What About Patients Without Insurance?

Genentech's Patient Foundation provides free Rozlytrek to qualifying patients who are uninsured or underinsured and cannot afford the medication. The Genentech Access Solutions team (877-436-3683) can refer patients to this program. Independent foundations such as the Patient Access Network Foundation (PANF), CancerCare, and the HealthWell Foundation may also provide copay assistance for insured patients whose out-of-pocket costs are unmanageable.

How Does Entrectinib Compare to Other Options?

If you're having access issues specifically with entrectinib, it's worth discussing alternatives with your oncologist. For ROS1-positive NSCLC, other FDA-approved options include repotrectinib (Augtyro), crizotinib (Xalkori), and taletrectinib (Ibtrozi). For NTRK fusion-positive tumors, larotrectinib (Vitrakvi) is another approved option. Read our full guide to alternatives to entrectinib for more detail.

The Bottom Line

Entrectinib is hard to find at a regular pharmacy because it was never meant to be there. It's a specialty oncology drug that requires biomarker testing, prior authorization, and ongoing monitoring — all things that specialty pharmacies handle better than retail stores. If you're hitting walls, start with your oncologist's office and Genentech Access Solutions, and don't hesitate to use tools like medfinder to track down which pharmacies can actually fill your script. See our guide to how to find entrectinib in stock near you for step-by-step tips.